Copertura documentale

Il Quality Gate pubblico registra 13 supporti documentali, 3 fonti indipendenti e 6 relazioni. Questi valori misurano documentazione e provenienza, non efficacia o appropriatezza clinica.

Documenti indicizzati collegati

• Folic acid-functionalized Exemestane-loaded chitosan nanoparticles: Synthesis, characterization and enhanced cytotoxicity against MCF-7 breast cancer cells — Crossref
• Unveiling the Research Landscape of Triazole-based Aromatase Inhibitors in Breast Cancer: Bibliometric Insights — Crossref
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment — ClinicalTrials.gov
• Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial — ClinicalTrials.gov
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer — ClinicalTrials.gov
• OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer — ClinicalTrials.gov
• Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic — ClinicalTrials.gov
• Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE) — ClinicalTrials.gov
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. — ClinicalTrials.gov
• Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer — ClinicalTrials.gov
• Sapu003 in Advanced mTOR-sensitive Solid Tumors — ClinicalTrials.gov
• Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer. — ClinicalTrials.gov

Collegamenti nel Knowledge Graph

• OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer — uses intervention
• Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial — uses intervention
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. — uses intervention
• Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic — uses intervention
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment — uses intervention
• Phase IIIb Study of Ribociclib + ET in Early Breast Cancer — uses intervention

Come interpretare questa pagina

Una relazione documentale non equivale a una raccomandazione. Risultati favorevoli nelle condizioni studiate, non favorevoli nelle condizioni studiate, non concordanti o con dati insufficienti restano consultabili nel motore con la loro provenienza.

Privacy

Questa pagina deriva esclusivamente dal patrimonio scientifico pubblico indicizzato. Il Publisher non usa IP, cookie, account, cronologia, fingerprint o ricerche individuali.

Quality Gate documentale: 91/100 · ultimo aggiornamento Settembre 29, 2026